To embed, copy and paste the code into your website or blog:
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Shire LLC v. Neos Therapeutics, Inc.
3:13-cv-01452; filed April 11, 2013 in the Northern District of Texas
Infringement of U.S. Patent Nos. RE42,096 ("Oral Pulsed Dose Drug Delivery System," issued February 1, 2011) and RE41,148 (same title, issued February 23, 2010) following a Paragraph IV certification as part of Neos filing of an NDA (under § 505(b)(2) of the Food, Drug and Cosmetic Act) to manufacture a generic version of Shire's Adderall XR® (a combination of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate, used to treat attention deficit hyperactivity disorder). View the complaint here.
Japanese Foundation for Cancer Research v. Rea et al.
1:13-cv-00412; filed April 1, 2013 in the Eastern District of Virginia
• Plaintiff: Japanese Foundation for Cancer Research
• Defendants: Teresa Stanek Rea; United States Patent and Trademark Office
Judicial review of the USPTO's refusal to grant a petition for withdrawal of an unauthorized disclaimer of the remaining term of U.S. Patent No. 6,194,187 ("Apoptosis-inducing Protein and Gene Encoding the Same," issued February 27, 2001). View the complaint here.
DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.
© McDonnell Boehnen Hulbert & Berghoff LLP
Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up to create your digest using LinkedIn*
Back to Top